Medical Research
(H99)
TRANSCELERATE BIOPHARMA INC
CharityAI™ Score
Not yet evaluated
Financial Overview — FY 2023
$34.2M
Total Revenue
$32.5M
Total Expenses
$11.6M
Net Assets
34
Employees
Revenue Sources
Expense Breakdown
Program Expense Ratio
71.4%
Fundraising Efficiency
0.0%
Operating Reserve
4.29x
Liability-to-Asset
75.9%
Revenue Diversification
97.7%
Financial History
| Year | Revenue | Expenses | Net Assets | Program % | Staff |
|---|---|---|---|---|---|
| 2023 | $34.2M | $32.5M | $11.6M | 71.4% | 34 |
| 2022 | $33.6M | $34.3M | N/A | — | 25 |
| 2021 | $31.1M | $33.2M | N/A | — | 26 |
Donor Reviews
No reviews yet
Be the first to share your experience with this organization.